Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage
News Jun 07, 2010
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, has announced the decision to advance the Phase II Hodgkin’s lymphoma (HL) SAPHIRE study with the HDAC inhibitor resminostat into the second Simon stage of patient recruitment.
This decision is based on the analysis of radiological imaging data from patients treated in the first Simon stage through an independent central assessment committee, which confirmed the achievement of the clinical activity requirements for the advancement of the trial.
4SC announced that the first patient had been treated in this trial on January 12, 2010. The Phase II SAPHIRE trial will continue into its second stage of patient recruitment and final results are expected, as planned, in the second half of 2011.
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
£70M Meant for Cancer Drug Development is Reassigned to Prepare for BrexitNews
At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.READ MORE